
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has demonstrated a robust revenue trajectory, with a two-year revenue CAGR projected to increase by 28% from 2023 to 2025, supported by the anticipated growth in colorectal cancer (CRC) diagnostics, breast cancer indications, and new monitoring applications. The company's recent launch of Shield, which exceeded revenue expectations, and the anticipated continued strong performance of Reveal, its fastest-growing test, are key contributors to an optimistic revenue outlook, with 2025 revenue guidance reflecting a 31% year-over-year growth. Additionally, Guardant Health’s market capitalization is poised to surpass $10 billion, driven by significant share price appreciation and increasing investor interest in its innovative product portfolio and expansion efforts.
Bears say
Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, contributing to concerns over the company's growth potential. The company reported an adjusted EBITDA loss of $45.5 million in Q3 2025, reflecting financial challenges that could exacerbate stock volatility in the face of any negative news regarding regulatory issues, reimbursement, or product launch timelines. Additionally, the firm's executive commentary indicates that reliance on ongoing research and development funding, coupled with potentially delayed international expansion due to regulatory obstacles, could continue to hinder financial performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares